Italia markets closed

FTSE MIB
35.398,82
-11,31(-0,03%)
Dow Jones
40.003,59
+134,21(+0,34%)
Nasdaq
16.685,97
-12,35(-0,07%)
Nikkei 225
38.787,38
-132,88(-0,34%)
Petrolio
80,00
+0,77(+0,97%)
Bitcoin EUR
61.435,11
+1.256,48(+2,09%)

NBIX Dec 2024 135.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

11,60

0,00

(0,00%)

In data: 03:24PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat